image
Healthcare - Biotechnology - NASDAQ - US
$ 27.5
15.5 %
$ 180 M
Market Cap
-2.3
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one TIL stock under the worst case scenario is HIDDEN Compared to the current market price of 27.5 USD, Instil Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one TIL stock under the base case scenario is HIDDEN Compared to the current market price of 27.5 USD, Instil Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one TIL stock under the best case scenario is HIDDEN Compared to the current market price of 27.5 USD, Instil Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TIL

image
$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.0$10.0$10.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
-73.5 M OPERATING INCOME
53.80%
-74.1 M NET INCOME
52.50%
-55.7 M OPERATING CASH FLOW
32.10%
54 M INVESTING CASH FLOW
31.23%
1.76 M FINANCING CASH FLOW
-78.29%
0 REVENUE
0.00%
-30.6 M OPERATING INCOME
-158.58%
-11.9 M NET INCOME
48.33%
-10.6 M OPERATING CASH FLOW
47.55%
13 M INVESTING CASH FLOW
-34.39%
1.6 M FINANCING CASH FLOW
903.77%
Balance Sheet Instil Bio, Inc.
image
Current Assets 124 M
Cash & Short-Term Investments 113 M
Receivables 0
Other Current Assets 11.2 M
Non-Current Assets 139 M
Long-Term Investments 0
PP&E 130 M
Other Non-Current Assets 8.76 M
42.99 %4.23 %49.45 %3.32 %Total Assets$263.6m
Current Liabilities 7.9 M
Accounts Payable 659 K
Short-Term Debt 1.68 M
Other Current Liabilities 5.56 M
Non-Current Liabilities 86.2 M
Long-Term Debt 85.2 M
Other Non-Current Liabilities 1.03 M
5.90 %90.52 %Total Liabilities$94.1m
EFFICIENCY
Earnings Waterfall Instil Bio, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 73.5 M
Operating Income -73.5 M
Other Expenses 594 K
Net Income -74.1 M
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)000(74m)(74m)(594k)(74m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-43.75% ROE
-43.75%
-28.13% ROA
-28.13%
-28.58% ROIC
-28.58%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Instil Bio, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)202020202021202120222022202320232024202420252025
Net Income -74.1 M
Depreciation & Amortization 3.61 M
Capital Expenditures 0
Stock-Based Compensation 17.3 M
Change in Working Capital -12.6 M
Others -1.87 M
Free Cash Flow -55.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Instil Bio, Inc.
image
Wall Street analysts predict an average 1-year price target for TIL of $113 , with forecasts ranging from a low of $40 to a high of $180 .
TIL Lowest Price Target Wall Street Target
40 USD 45.45%
TIL Average Price Target Wall Street Target
113 USD 312.12%
TIL Highest Price Target Wall Street Target
180 USD 554.55%
Price
Max Price Target
Min Price Target
Average Price Target
180180160160140140120120100100808060604040202000Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Instil Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the clearance of an Investigational New Drug (IND) application for AXN-2510 (“'2510”) by the U.S. Food and Drug Administration. Instil expects to initiate a phase 1 trial of ‘2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025. globenewswire.com - 1 week ago
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 3 weeks ago
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet The mean of analysts' price targets for Instil Bio (TIL) points to a 246.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 3 weeks ago
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Instil's wholly-owned subsidiary dedicated to the development of AXN-2510 (“'2510”), a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer (NSCLC). globenewswire.com - 1 month ago
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 1 month ago
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman brings deep experience in oncology drug development and other therapeutic areas, and a track record of leading programs through all phases of development, regulatory approval and commercialization. globenewswire.com - 1 month ago
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that Bronson Crouch, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference at 4:20PM ET on Thursday, June 5, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/jeff319/til/1708376. globenewswire.com - 1 month ago
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? Instil Bio (TIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 month ago
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade The consensus price target hints at a 343.6% upside potential for Instil Bio (TIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success Key catalyst: Phase 2 data from China in first-line NSCLC expected in 2H 2025, with enrollment completion projected for Q3 2025. The global non-small cell lung cancer therapeutics market size is projected to reach $66.20 billion by 2033. The U.S. strategy differs, focusing on dose-optimization as a bridging study for a future global phase 3 registration trial. seekingalpha.com - 1 month ago
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research analyst breakfast in Chicago, Illinois on Saturday, May 31, 2025 at 8:00 to 9:30 am CT adjacent to the McCormick Convention Center. globenewswire.com - 1 month ago
8. Profile Summary

Instil Bio, Inc. TIL

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 180 M
Dividend Yield 0.00%
Description Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Contact 3963 Maple Avenue, Dallas, TX, 75219 https://instilbio.com
IPO Date March 19, 2021
Employees 14
Officers Dr. Sandeep Laumas M.D. Chief Financial Officer & Chief Business Officer Mr. Bronson Crouch Chairman & Chief Executive Officer